The associate professor at Fred Hutch Cancer Center discussed trends he observed in the field in 2023 and at ASH 2023.
“At the end of the day, retrospective studies are important but only affirmative in clinical decisions, and one needs to consider the limitations that come with such an analysis. So, we want to make sure that access to CAR-T is improved and those patients get to CAR-T. But there may be patients who can benefit from this data, in terms of knowing about their additional choices for therapy.”
Auto-hematopoietic stem cell transplant (HSCT) is associated with a lower relapse rate and an improved progression-free survival compared to chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed large B-cell lymphoma (LBCL) who achieve a complete or partial response with bridging chemotherapy.
These data, from a retrospective analysis, were presented by Mazyar Shadman, MD, MPH, associate professor, clinical research division, and attending physician, hematologic malignancies, Fred Hutch Cancer Center, and associate professor, medical oncology division, University of Washington School of Medicine, at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, held December 9-12, in San Diego, California. Shadman and colleagues observed these findings in patients with LBCL naive to both treatments, including those with early treatment failure within 12 months.
CGTLive spoke with Shadman to learn more about the importance of the new findings and the takeaways that clinicians should take from them. He discussed more research he would like to see, as well as other research he worked on presented at ASH on ibrutinib and zanubrutinib. He also discussed research trends from 2023, including a focus on combination and sequencing therapies.